The company is dedicating more funds to research, development and innovative projects.
It’s too early to tell how the new administration will affect the device industry, but user fees, the ACA and the FDA regulatory process are top of mind.
Market growth can be attributed to a healthy pipeline of science and medical research institutes.
Perhaps the organizational soul searching should begin after receiving one Form 483.
We all talk about cross-collaboration, but do we really practice it?